Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
VNRX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-0.14
vs -0.14
Q3.23
N/A
-0.11
vs -0.14
Q4.23
N/A
-0.11
vs -0.13
Q1.24
N/A
-0.10
vs -0.15
Q2.24
N/A
-0.08
vs -0.14
Q3.24
N/A
-0.07
vs -0.11
Q4.24
N/A
-0.11
vs -0.11
Q1.25
N/A
NA
vs -0.10
Q2.25
N/A
-0.05
vs -0.08
Q3.25
N/A
-0.04
vs -0.07
Sales Growth
YoY
Current
Estimates
Q2.23
+444%
216.3K vs 39.8K
Q3.23
+405%
165.2K vs 32.7K
Q4.23
+104%
244K vs 119.7K
Q1.24
+15%
171.5K vs 149.8K
Q2.24
+83%
395.8K vs 216.3K
Q3.24
+187%
474.5K vs 165.2K
Q4.24
-21%
191.7K vs 244K
Q1.25
+44%
246.4K vs 171.5K
Q2.25
+35%
533.5K vs 395.8K
Q3.25
+123%
1.1M vs 474.5K
Return on Equity
QoQ
Q2.23
-162%
-1.62
vs 3.76
Q3.23
+410%
4.1
vs -1.62
Q4.23
+111%
1.11
vs 4.1
Q1.24
+54%
0.54
vs 1.11
Q2.24
+32%
0.32
vs 0.54
Q3.24
+27%
0.27
vs 0.32
Q4.24
+23%
0.23
vs 0.27
Q1.25
+26%
0.26
vs 0.23
Institutionnal Ownership
QoQ
Q2.23
38
38
vs 43
-12%
Q3.23
31
31
vs 38
-18%
Q4.23
29
29
vs 31
-6%
Q1.24
24
24
vs 29
-17%
Q2.24
29
29
vs 24
21%
Q3.24
24
24
vs 29
-17%
Q4.24
28
28
vs 24
17%
Q1.25
24
24
vs 28
-14%
prnewswire.com
8 hours ago
prnewswire.com
8 hours ago
prnewswire.com
17 hours ago
seekingalpha.com
19 hours ago
prnewswire.com
21 hours ago
Quote Panel
Key Metrics
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
AMEX
Unprofitable
EPS improving
Unprofitable
EPS improving
0.08Â ( 12.48%)
Pre-market 0.76$0.04 (5.58%)
Relative Strenght
80
Volume Buzz
102%
Earning Acce
Yes
Dist 52w H.
21%Forecast
6632%2026-Revenue
-6%2026-EPS
-227%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Relative Strength
VNRX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|